Redesigned Scorpion Venom Peptides Kill Drug-Resistant Acinetobacter With Less Toxicity | Research

The takeaway

Modified analogs of scorpion peptide Hp1404 showed improved antibacterial activity against multidrug-resistant Acinetobacter baumannii and reduced cytotoxicity, killing bacteria by disrupting both outer and inner membranes and inhibiting biofilm formation.

Active against WHO critical pathogen
Modified scorpion peptides kill multidrug-resistant A. baumannii — classified as the #1 critical priority pathogen by WHO — with reduced human cell toxicity

What the researchers found

Hp1404 analog peptides showed reduced cytotoxicity, enhanced activity against MDR A. baumannii, dual membrane disruption (outer + cytoplasmic), and improved biofilm inhibition at low concentrations compared to parent peptide.

Why it matters

MDR A. baumannii is classified as a critical priority pathogen by WHO. Peptides that kill it through membrane disruption and biofilm prevention address an urgent unmet medical need where traditional antibiotics are failing.

The numbers in context

14 C-terminal residues modified; active against MDR A. baumannii; membrane permeabilization (NPN, DiSC3-5); biofilm inhibition; lower cytotoxicity

How the study worked

In vitro study. Amino acid substitution at 14 C-terminal positions of scorpion peptide Hp1404. Antimicrobial testing against gram-positive and gram-negative bacteria. Cytotoxicity assessment. Membrane permeabilization (NPN uptake, DiSC3-5). Biofilm inhibition assays.

Who was studied

Multidrug-resistant A. baumannii and other gram-positive/gram-negative bacteria

What this study cannot tell us

In vitro testing only. No animal infection model data. Peptide stability in biological fluids not assessed. Manufacturing scalability and cost not addressed.

How to read the evidence

Low evidence grade: in vitro antimicrobial testing only. Promising activity data but no animal or clinical studies.

When this study was published

Published 2021. Antimicrobial peptide optimization for drug-resistant bacteria continues as a high-priority research area.

The bigger picture

This study demonstrates how nature's antimicrobial peptides can be rationally redesigned for clinical use — reducing toxicity while maintaining or improving antibacterial potency. The approach could be applied to other venom-derived peptides.

Questions still open

Would these analog peptides be effective in vivo against A. baumannii wound or lung infections?
Can the peptides be further optimized for systemic or topical delivery?
Would bacteria develop resistance to these membrane-disrupting peptides over time?

Common questions

What is Acinetobacter baumannii and why is it so dangerous?

A. baumannii is a superbug commonly found in hospitals that has developed resistance to nearly all available antibiotics. It causes pneumonia, bloodstream infections, and wound infections, particularly in ICU patients. The WHO ranks it as the #1 critical priority pathogen needing new antibiotics.

How do these peptides avoid the toxicity problem?

The original scorpion peptide was effective but damaged human cells too. By strategically changing specific amino acids, researchers reduced the peptide's attraction to human cell membranes while maintaining its ability to disrupt bacterial membranes — essentially making it more selective for bacteria.

Read the original research

Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against Acinetobacter baumannii.

International journal of molecular sciences, 22(11)

View on PubMed ↗Publisher’s paper ↗

Citation

Hong, Min Ji; Kim, Min Kyung; Park, Yoonkyung. (2021). Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against Acinetobacter baumannii.. International journal of molecular sciences, 22(11). https://doi.org/10.3390/ijms22115540